J Vet Sci.  2013 Dec;14(4):495-497. 10.4142/jvs.2013.14.4.495.

Percutaneous transplantation of human umbilical cord-derived mesenchymal stem cells in a dog suspected to have fibrocartilaginous embolic myelopathy

Affiliations
  • 1Department of Veterinary Surgery, College of Veterinary Medicine, Konkuk University, Seoul 143-701, Korea. hykim@konkuk.ac.kr
  • 2Seoul Cord Blood Bank, Histostem Co., Seongnam 462-807, Korea.

Abstract

The use of human umbilical cord blood-derived mesenchymal stem cells for cell transplantation therapy holds great promise for repairing spinal cord injury. Here we report the first clinical trial transplantation of human umbilical cord (hUCB)-derived mesenchymal stem cells (MSCs) into the spinal cord of a dog suspected to have fibrocartilaginous embolic myelopathy (FCEM) and that experienced a loss of deep pain sensation. Locomotor functions improved following transplantation in a dog. Based on our findings, we suggest that transplantation of hUCB-derived MSCs will have beneficial therapeutic effects on FCEM patients lacking deep pain sensation.

Keyword

dog; fibrocartilaginous embolic myelopathy; human umbilical cord-derived mesenchymal stem cells; percutaneous transplantation; xenotransplantaion

MeSH Terms

Animals
Cartilage Diseases/etiology/therapy/*veterinary
*Cord Blood Stem Cell Transplantation/veterinary
Dog Diseases/etiology/*therapy
Dogs
Embolism/etiology/therapy/*veterinary
Female
Humans
Mesenchymal Stromal Cells/cytology/*metabolism
Spinal Cord Diseases/etiology/therapy/*veterinary
Treatment Outcome
Full Text Links
  • JVS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr